AstraZeneca: equity investment in Cellectis
As a reminder, in the fourth quarter of 2023, Cellectis received an upfront payment of $105 million from AstraZeneca, which included an initial cash payment of $25 million.
An additional equity investment of $140 million, at $5/share, has closed.
After this second investment, AstraZeneca holds a total stake of around 44% in Cellectis.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction